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ABSTRACT
Proteins involved in tumor cell migration can potentially serve as markers of 
invasive disease. Activated Leukocyte Cell Adhesion Molecule (ALCAM) promotes 
adhesion, while shedding of its extracellular domain is associated with migration. 
We hypothesized that shed ALCAM in biofluids could be predictive of progressive 
disease. ALCAM expression in tumor (n = 198) and shedding in biofluids (n = 120) 
were measured in two separate VUMC bladder cancer cystectomy cohorts by 
immunofluorescence and enzyme-linked immunosorbent assay, respectively. The 
primary outcome measure was accuracy of predicting 3-year overall survival (OS) with 
shed ALCAM compared to standard clinical indicators alone, assessed by multivariable 
Cox regression and concordance-indices. Validation was performed by internal 
bootstrap, a cohort from a second institution (n = 64), and treatment of missing data 
with multiple-imputation. While ALCAM mRNA expression was unchanged, histological 
detection of ALCAM decreased with increasing stage (P = 0.004). Importantly, urine 
ALCAM was elevated 17.0-fold (P < 0.0001) above non-cancer controls, correlated 
positively with tumor stage (P = 0.018), was an independent predictor of OS after 
adjusting for age, tumor stage, lymph-node status, and hematuria (HR, 1.46; 95% 
CI, 1.03–2.06; P = 0.002), and improved prediction of OS by 3.3% (concordance-
index, 78.5% vs. 75.2%). Urine ALCAM remained an independent predictor of OS after 
accounting for treatment with Bacillus Calmette-Guerin, carcinoma in situ, lymph-node 
dissection, lymphovascular invasion, urine creatinine, and adjuvant chemotherapy 
(HR, 1.10; 95% CI, 1.02–1.19; P = 0.011). In conclusion, shed ALCAM may be a novel 
                  Research Paper
Oncotarget723www.impactjournals.com/oncotarget
INTRODUCTION
Bladder cancer (BCa) is the 9th most common 
cancer world-wide [1] and 4th most common in men in 
the USA with an estimated 74,000 new cases in 2015 [2]. 
Approximately 20–30% of BCa is diagnosed as muscle 
invasive (MIBC) while 10–30% of patients with non-
muscle invasive BCa (NMIBC) progress to invasive 
disease [3, 4]. While surgical resection of the bladder 
(cystectomy) can be curative, approximately 50% of 
cystectomy patients recur with metastases within two years 
[5]. The risk of progression and recurrence necessitates 
frequent follow-up, invasive monitoring, and repeated 
clinical interventions, which decreases quality of life and 
makes lifelong management of BCa more costly than 
any other cancer [6]. Moreover, despite proven survival 
benefit, neoadjuvant chemotherapy is under-utilized in this 
aging patient population with multiple comorbidities [7, 8]. 
Prognostic indicators could identify patients likely to 
benefit from aggressive intervention and improve patient 
care but there are currently no accurate, non-invasive ways 
to predict recurrence and monitor treatment response. 
Accessibility makes fluid-based biomarkers 
attractive candidates for the diagnosis and prognosis of 
BCa [9]. Unfortunately, only a small proportion of fluid-
based biomarkers have been investigated for prognostic 
significance in BCa, with the majority of studies focused 
on diagnostics [10, 11]. A recent multiplatform genomic 
analysis highlights the molecular heterogeneity of bladder 
cancer [12] and underscores the diversity of oncogenic 
mechanisms that can drive bladder cancer. However, 
post-translational modifications that universally support 
malignant progression, such as proteolytic products of cell 
motility, are promising biomarkers that may act as global 
predictors of patient outcome regardless of the underlying 
genetics [13]. Activated Leukocyte Cell Adhesion Molecule 
(ALCAM) is a cell surface protein capable of homotypic 
cell-cell adhesion [14–17], the disruption of which, 
contributes to both normal cell migration and the metastatic 
dissemination of tumor cells [18, 19]. ALCAM-mediated 
adhesion is disrupted when its ectodomain is shed by 
ADAM17 from the surface of tumor cells during malignant 
transformation [20–22]. Consequently, ALCAM shedding is 
a molecular indicator of a cellular activity that will ultimately 
present itself pathologically as invasive and/or disseminated 
disease. Indeed, we have recently demonstrated that, through 
preclinical studies of prostate cancer and clinical correlation 
in colorectal cancer, ALCAM contributes directly to cancer 
metastasis [22] and histological detection of intra-tumoral 
ALCAM shedding is prognostic of disease-specific survival 
in stage II disease [23].
ALCAM has significant potential as a fluid-based 
biomarker because the shed ectodomain of ALCAM is 
released into adjacent biofluids. While elevated serum levels 
of ALCAM have been reported for several non-urothelial 
neoplasms [20, 24–28], high baseline levels of circulating 
ALCAM prevent its global implementation as a blood-based 
biomarker. However, studies of ALCAM in ascites fluid 
from patients with ovarian carcinomatosis suggest ALCAM 
in tumor-adjacent fluids, other than blood, could predict 
outcome [23, 24]. In the bladder, ALCAM expression is 
restricted to the umbrella cells and several layers of the 
urothelium, which are in direct contact with the urine. 
Therefore, we hypothesized that elevated levels of urinary 
ALCAM would be indicative of invasive tumor progression 
and, thus, serve as a prognostic biomarker in BCa. Using 
retrospective cohort studies, we compared the ability of 
ALCAM gene expression (mRNA), tissue expression 
(protein), and shedding (blood and urine) to predict overall 
survival in BCa. This is the first study to provide a multi-
level assessment of ALCAM prognostication in cancer and 
definitively show that it is post-translational processing 
of ALCAM, defined as ALCAM “shedding”, that is most 
predictive of patient outcome.
RESULTS
ALCAM gene expression
Analysis of ALCAM mRNA expression was 
performed on four independent bladder cancer cohorts 
available as GEO datasets at NCBI (GSE31684, n = 93; 
GSE48276, n = 126; GSE13507, n = 176; GSE3167, 
n = 46) [29–32]. A comparison of non-muscle invasive 
(NMIBC) and muscle invasive (MIBC) bladder cancer 
revealed that ALCAM expression is not significantly altered 
during BCa progression to invasive disease (Figure 1A). 
To further determine if ALCAM mRNA expression 
correlated with outcome in BCa, we performed a detailed 
statistical analysis of the GSE31684 dataset [32]. 
ALCAM mRNA expression did not correlate with tumor 
stage (Kruskal-Wallis (K-W), P = 0.722; Jonckheere-
Terpstra test for trend (J-T), P = 0.610; Figure 1B), 
nor did it significantly stratify patient outcome of 
overall survival when dichotomized around the median 
log2 mRNA level of 10.4 (Log-rank, P = 0.325; 
Hazards Ratio (HR), 1.25; 95% Confidence Interval 
(CI), 0.75–2.07; Figure 1C). Furthermore, multivariable 
Cox regression analysis reveals that ALCAM gene 
expression fails to reach significance as an independent 
predictor of 3-year overall survival after adjusting for 
available covariates including age, gender and tumor 
stage (Table 1 Top; adjusted HR, 1.26; 95% CI, 0.94–
1.68; p = 0.118). Since ALCAM mRNA levels remain 
unaltered during tumor progression in four independent 
patient cohorts and fail to predict overall survival by 
prognostic biomarker in bladder cancer, although prospective validation studies are 
warranted. These findings demonstrate that markers reporting on cell motility can 
act as prognostic indicators.
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Table 1: Assessment of ALCAM mRNA and protein expression as a predictor in a multivariable 
Cox regression analysis of 3-year overall survival in bladder cancer
Variable Hazard Ratio 95.0% CI Significance Bootstrap Significance
Age (Years) 1.01 a 0.98–1.04 0.404 0.384
Gender 1.32 a 0.70–2.48 0.396 0.383
Tumor Stage 2.46 a 1.69–3.58 < 0.0001 0.001
ALCAM Log2 mRNA 1.26 a 0.94–1.68 0.118 0.107
Age (Years) 1.03 a 1.01–1.05 0.01 0.024
Gender 0.78 0.50–1.21 0.265 0.304
Tumor Stage 1.30 a 1.12–1.50 0.001 0.001
N Stage 1.42 1.10–1.82 0.006 0.017
ALCAM (% Thresholded Area) 1.00 a 0.99–1.02 0.843 0.792
Assessment of ALCAM mRNA (top) and protein (bottom) expression as a predictor of 3-year overall survival by multivariable 
Cox regression analysis. The mRNA expression cohort is a publicly available dataset at NCBI Gene Expression Omnibus 
(GEO) [GSE31684] [32]. The ALCAM protein expression was measured by fluorescence intensity (% thresholded area) in 
the VUMC bladder cancer TMA cohort as described in Table 2. Hazard Ratio is the adjusted hazards ratio for a every 1 unit 
increase such as 1 year or 1%. CI, confidence interval. Bootstrap significance is two-tailed with 1000 iterations and a Mersenne 
twister of 2,000,000. 
Figure 1: Correlation of ALCAM mRNA with tumor progression and overall survival in bladder cancer. (A) Gene 
expression analyses performed on four independent bladder cancer cohorts, GSE31684 (n = 93), GSE48276 (n = 126), GSE13507 
(n = 176), and GSE3167 (n = 46), available as GEO datasets on NCBI Gene Expression Omnibus comparing Log2 mRNA ALCAM levels of 
non-muscle invasive (NMIBC) and muscle invasive (MIBC) bladder cancer [29–32]. Mean and 95% confidence intervals displayed. (B–C) 
Analysis of the GSE31684 dataset for ALCAM Log2 mRNA correlation with tumor stage (B) and overall survival (C). (B) Mean and 95% 
confidence intervals displayed. K-W, Kruskal-Wallis test. J-T, Jonckheere-Terpstra test for trend. (C) Kaplan-Meier curves and Log-rank test 
for significance of ALCAM dichotomized high/low around the median Log2 mRNA level (10.4). HR, Hazard Ratio. CI, Confidence Interval. 
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univariable and multivariable analyses, we conclude that 
ALCAM gene expression is not a viable biomarker for 
BCa prognosis. 
ALCAM protein expression
Post-translational proteolytic processing of ALCAM 
can create a disparity between gene expression and the 
availability of ALCAM protein.  Indeed, ALCAM protein 
levels frequently fail to correlate with gene transcription 
[33]. In addition, histological detection of ALCAM has 
been shown to correlate with disease progression and patient 
outcome in several non-urothelial cancers [26, 27, 33–38].
To determine if protein expression of ALCAM in 
BCa correlates with tumor stage and/or patient outcome, 
we performed immunofluorescence staining on tissue 
microarrays (TMAs) constructed of high-grade BCa 
specimens collected during cystectomy (Table 2) as 
described in the methods. The final readout for ALCAM 
was a continuous variable defined as the area within the 
region of interest (epithelium) that was above background 
(% thresholded area). In normal bladder, ALCAM protein 
expression was confined to the urothelium (Figure 2A, 
Normal). In non-invasive carcinoma in situ, the expansion 
of the urothelium led to an increase in ALCAM positive 
cells with no increase in signal intensity (Figure 2A, CIS). 
However, concomitant with the appearance of an invasive 
phenotype, ALCAM detection and fluorescence intensity 
diminished in the progression from pT1 to pT4 (Figure 2A). 
Since each patient had multiple cores representing 
several pathological stages and, thus, had non-independent 
samples, the correlation of the mean ALCAM intensity score 
with pathological core stage was analyzed with generalized 
estimating equations (GEE) ordinal logistic regression 
and Kendall’s rank correlation (K) (n = 481). Based on 
these analyses, ALCAM was significantly and inversely 
correlated with core stage, demonstrating a loss of ALCAM 
detection with advanced stage (K, τ = −0.16; p = 0.004; 
GEE OR, 1.04; 95% CI, 1.03–1.05; p < 0.0001; Figure 
2B). In other words, there is a 4% increased odds of higher 
stage with every 1% decrease in ALCAM thresholded area. 
However, subsequent overall survival analysis performed 
using only invasive core values (n = 198) revealed that 
ALCAM expression failed to correlate with overall survival 
when percent thresholded area was dichotomized around the 
mean of 6.66% (Log-Rank, P = 0.413; HR, 1.18; 95% CI, 
0.79–1.76; Figure 2C). Most importantly, ALCAM protein 
expression was not a significant predictor of overall survival 
when treated as a continuous covariate and adjusted for age, 
gender, tumor stage and lymph-node status by multivariable 
Cox regression analysis (Table 1 Bottom; adjusted HR, 
1.00; 95% CI, 0.99–1.02; p = 0.843). These observations 
demonstrate that, in spite of a strong correlation between 
ALCAM protein detection and tumor stage, ALCAM 
expression fails to independently correlate with or predict 
patient outcome.
ALCAM shedding
While the detection of ALCAM protein within 
the tumor tissue is reduced with disease progression, 
such a trend was not observed in gene expression. Since 
immunofluorescence staining for ALCAM was performed 
with an antibody against the extracellular domain, we 
suspected that the loss of ALCAM in BCa tissue was 
likely due to proteolytic shedding of the ectodomain [20, 
21]. Consequently, we hypothesized that ALCAM shed 
by malignant urothelium should be detectable in adjacent 
biofluids such as blood and urine (Figure 3A).
We first wanted to determine if ALCAM is 
detectable in biofluid and, if so, verify that it is, indeed, 
shed ALCAM and not just intact ALCAM derived from 
cellular debri or exosomes. Not only was ALCAM 
detectable, immunoblots of urine from patients with 
bladder cancer as well as, from tumor cell lysates and 
conditioned media, reveal two pieces of evidence verifying 
biofluid ALCAM is actually proteolytically cleaved, shed 
ALCAM (Figure 3B). First, there is a downward shift in 
the size of ALCAM detected in conditioned media and 
urine compared to that detected in lysate (MOG/07; Figure 
3B, Left). Second, the monoclonal antibody, 1G3A, that 
is against the intracellular domain of ALCAM can only 
detect ALCAM in the cell lysate, indicating that ALCAM 
in the tumor cell conditioned media and urine is lacking 
this intracellular domain (1G3A; Figure 3B, Right).
Shed ALCAM levels in serum and urine
We next analyzed serum and urine ALCAM levels 
by ELISA from patients in four distinct biofluid cohorts 
including: 1) patients undergoing surgery but with no cancer 
(Normal Controls), 2) patients with inflammatory diseases 
(Inflammation), 3) patients with non-bladder malignancies 
(General Cancer) and 4) patients with high-grade bladder 
cancer (BCa). Analysis of serum ALCAM revealed that 
it was moderately elevated in BCa patients compared to 
Normal Controls (Figure 3C; 1.3-fold, P < 0.0001). In 
contrast, the level of ALCAM in urine from BCa patients 
was dramatically elevated when compared to Normal 
Controls (Figure 3D; 17.0-fold, P < 0.0001). Urinary 
ALCAM levels were also measured for patients with 
inflammatory diseases or other cancers to confirm that the 
significant elevation of urine ALCAM was specific to the 
presence of BCa. These non-BCa urines did show elevated 
levels of ALCAM when compared to normal controls 
(Figure 3D; 5.6 and 6.6-fold; P = 0.0183 and P < 0.0001) 
but still contained significantly less ALCAM than the BCa 
urines (Figure 3C; 3.0 and 2.5-fold; both P < 0.0001).
Quality control
Quality control assays were performed to ensure 
that a commercially available ELISA test of ALCAM was 
sufficiently repeatable (i.e. reproducible within the same 
Oncotarget726www.impactjournals.com/oncotarget
Table 2: Bladder cancer TMA ALCAM expression cohort descriptors and frequencies
N Quartiles Mean ± SD
Age (Years) 198 59, 67, 73 66 ± 11
ALCAM % Thresholded Area (IF) 198 0.33, 1.64, 6.50 6.56 ± 11.69
Follow-up (Months) 198 9.3, 25.4, 54.0 33.4 ± 27.3
Time to Death 3 Years (Months) 109 4.2, 12.6, 18.7 12.4 ± 9.0
Time to Death (Months) 130 5.5, 14.1, 25.5 18.4 ± 16.4
N Percent Frequency
Gender 198
Female 21.2% 42
Male 78.8% 156
Race 198
White 93.4% 185
Black 4.5% 9
Other 2.0% 4
Death (Full Follow-up) 198
0 34.3% 68
1 65.7% 130
Death (3 years) 198
0 44.9% 89
1 55.1% 109
Pathological Tumor Stage 198
pTaΨ 0.5% 1
pTisΨ 0.5% 1
pT1 10.6% 21
pT2a 17.2% 34
pT2b 18.7% 37
pT3a 21.2% 42
pT3b 15.7% 31
pT4a 15.2% 30
pT4b 0.5% 1
N Stage 198
N0 71.2% 141
N1 10.6% 21
N2 18.2% 36
Core Stage 481
Normal 29.3% 141
pTa 5.6% 27
pTis 24.3% 117
pT1 4.4% 21
pT2 14.8% 71
pT3 15.2% 73
pT4 6.4% 31
Description of the bladder cancer TMA patient cohort used for prognostic assessment of ALCAM expression by 
immunohistochemistry and immunofluorescence. There are 301 patients represented in the TMA with 657 cores total. Cores 
were classified by a pathologist as normal, pTis, pTa or “invasive” with each patient having multiple stages represented in 
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laboratory). Urinary ALCAM measurements were not 
significantly influenced by freeze-thaw (Supplementary 
Figure S1A), collection method (Supplementary Figure 
S1B; foley-derived vs. clean catch urine), or assay 
variation (Supplementary Figure S1C and S1D; 4–12% 
inter-assay variation). 
Shed ALCAM and univariable overall survival 
correlation
Since both serum and urine ALCAM concentrations 
were elevated in BCa, we set out to determine if either 
correlated with tumor stage and/or patient outcome using 
the VUMC cohort (Table 3, n = 120). Serum ALCAM 
levels did not show correlation with pathological tumor 
stage (Figure 3E; Kruskal-Wallis (K-W), P = 0.595; 
Jonckheere-Terpstra test for trend (J-T), P = 0.943). 
Urine ALCAM levels were not significantly different 
between tumor stages but did show a significant positive 
trend (Figure 3F; K-W, P = 0.058; J-T, P = 0.018), 
suggesting that ALCAM shedding increases with invasive 
progression. Next, Kaplan-Meier curves for overall 
survival were plotted for tumor stage, urine ALCAM 
and serum ALCAM (Figure 4A–4C). As expected, 
advanced tumor stage (≥ pT3, high stage) significantly 
correlated with decreased survival (Figure 4A; median 
overall survival (OS), 94 vs. 15 months; Log-Rank, 
P < 0.0001; HR, 3.46; 95% CI, 2.12–5.64). Urinary 
ALCAM dichotomized around the median of 2.18 ng/
ml also significantly stratified patients into high and low 
risk of death (Figure 4B; median OS, 62 vs. 23 months; 
Log-Rank, P = 0.048; HR, 1.64; 95% CI, 1.003–2.69). 
However, serum ALCAM dichotomized around the 
median of 74.88 ng/ml did not show correlation with 
overall survival (Figure 4C; Log-Rank, P = 0.929; 
HR, 1.02; 95% CI, 0.63–1.65). In order to evaluate the 
potential predictive power or confounding effect of 
each variable in our multivariable regression analysis, 
we computed Somers’ Dxy rank correlation between 
each variable and 3-year OS time considering censoring 
Figure 2: Correlation of intratumoral ALCAM protein expression with tumor stage and overall survival in bladder 
cancer. Correlation of ALCAM protein expression by immunofluorescence (IF) in the BCa TMA cohort with tumor stage (A, B) and 
overall survival (C). (A) IF for ALCAM (green), Ki67 (white), Collagen (red), and Nuclei (blue) in normal bladder and BCa (CIS, pT1, 
pT2, pT3, pT4). Scale bars = 100 µm (low magnification) and 50µm (high magnification). (B) Correlation of core stage (n = 481) and 
ALCAM IF percent thresholded area with GEE ordinal logistic regression (OR, odds ratio; with 95% CI) and Kendall’s (K) rank correlation 
(τ). Mean and 95% CI displayed. (C) Kaplan-Meier curves and Log-rank test for overall survival (n = 198) with ALCAM IF expression 
dichotomized around the mean percent thresholded area of 6.66%. HR, Hazard Ratio. CI, Confidence Interval.
the TMA. Only patients with invasive cores (n = 198) were utilized for overall survival analysis to prevent patients from being 
represented more than once. The mean of identically classified cores for each patient (n = 481) was calculated and used in the 
correlation of ALCAM expression with core stage. Quartiles (25%, Median, 75%) along with mean and standard deviation 
(SD) are given. Ψ, pathologist classified core as invasive even though the pathological staging was pTa and CIS.
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Table 3: Bladder cancer “shed” ALCAM cohort descriptors and frequencies
VUMC (n = 120) UTSW (n = 64) Comparison Combined Cohort (n = 184)
N Quartiles Mean ± SD N Quartiles Mean ± SD Test Statistic Significance N Quartiles Mean ± SD
Age (Years) 120 62, 69, 75 68 ± 10 63 63, 70, 77 69 ± 10 U = 3434a 0.311 183 63, 69, 75 68 ± 10
Serum 
ALCAM 
(ng/ml)
117 58.8, 74.9, 96.7 79.2 ± 26.3 29
53.6, 61.8, 
68.6 69.1 ± 36.8 U = 1096
a 0.003* 146 57.6, 70.7, 90.5 77.2 ± 28.8
Urine 
ALCAM 
(ng/ml)
111 0.78, 2.18, 6.18 4.05 ± 4.68 64
0.68, 1.35, 
2.51 2.08 ± 2.24 U = 2755
a 0.013* 175 0.73, 1.72, 4.24 3.33 ± 4.07
Urine 
Hemoglobin 
(μg/ml)
108 45, 341, 1088 1285 ± 2923 63
301, 503, 
1055
1205 ± 
2968 U = 2706
a 0.025* 171 128, 448, 1088 1256 ± 2931
Follow-up 
(Months) 120
12.6, 38.1, 
57.1 38.0 ± 57.1 59
5.0, 12.5, 
29.3 18.3 ± 15.9 U = 2170
a < 0.001* 179 8.7, 26.0, 49.3 31.5 ± 27.3
Time to 
Death 
3 Years 
(Months)
56 2.8, 11.1, 21.7 12.5 ± 10.4 20 1.7, 7.3, 17.1 9.5 ± 9.2 U = 455a 0.219 76 2.7, 9.3, 20.9 11.7 ± 10.1
N Percent Frequency N Percent Frequency Test Statistic Significance N Percent Frequency
Gender 120 62 χ21 = 3.23
b 0.224 182
 Female 10.0% (12) 9.7% (6) 9.9% (18)
 Male 90.0% (108) 90.3% (56) 90.1% (164)
Race 120 64 χ22 = 8.32
b 0.014* 184
 White 95.8% (115) 89.1% (57) 93.5% (172)
 Black 2.5% (3) 4.7% (3) 3.3% (6)
 Other 1.7% (2) 6.3% (4) 3.3% (6)
Pathological 
Tumor 
Stage
120 63 χ28 = 5.66
b 0.586 183
 pT0 4.2% (5) 7.9% (5) 5.5% (10)
 pTa 6.7% (8) 1.6% (1) 4.9% (9)
 pTis 7.5% (9) 7.9% (5) 7.7% (14)
 pT1 6.7% (8) 9.5% (6) 7.7% (14)
 pT2a 16.7% (20) 19.0% (12) 17.5% (32)
 pT2b 9.2% (11) 15.9% (10) 11.5% (21)
 pT3a 25.8% (31) 17.5% (11) 23.0% (42)
 pT3b 7.5% (9) 7.9% (5) 7.7% (14)
 pT4a 15.8% (19) 12.7% (8) 14.8% (27)
N Stage 120 60 χ23 = 5.85
b 0.088 180
 N0 75.0% (90) 73.3% (44) 74.4% (134)
 N1 5.0% (6) 10.0% (6) 6.7% (12)
 N2 20.0% (24) 13.3% (8) 17.8% (32)
 N3 0.0% () 3.3% (2) 1.1% (2)
Positive 
Lymph-
node Status
120 60 χ21 = 0.06
c 0.809 180
 0 75.0% (90) 73.3% (44) 74.4% (134)
 1 25.0% (30) 26.7% (16) 25.6% (46)
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(univariable predictive power) [39]. Tumor stage, positive 
lymph-node status, age and urine ALCAM had relatively 
high correlation with survival time compared to urine 
hemoglobin and serum ALCAM (Figure 4D). Therefore, 
we chose to exclude serum ALCAM from subsequent 
multivariable analyses but retain urine hemoglobin as an 
a priori defined control for urine ALCAM since there is 
no other way to exclude the possibility that elevated urine 
ALCAM could be a result of hematuria rather than direct 
tumor shedding.
Urinary ALCAM and multivariable analysis for 
prediction of 3-year overall survival
To determine if urine ALCAM was an independent 
predictor of OS, multivariable Cox regression analyses 
were performed on this same retrospective biofluid 
cohort (Table 3, VUMC, n = 120). Race and gender 
were excluded from all multivariable analyses since the 
VUMC cohort is 95.8% white and 90.0% male. As stated 
previously, urine hemoglobin was retained in further 
analyses since there was concern that hematuria would be 
a confounder for urine ALCAM. Therefore, the baseline 
model (Model 1) that was used to assess the benefit of 
adding urine ALCAM to predict 3-year OS included 
age, tumor stage, positive lymph-node status, and urine 
hemoglobin (Table 4). As expected, age, tumor stage, 
and positive lymph-node status were all independent 
predictors of 3-year OS (Table 4; Model 1; P < 0.001, 
P = 0.006, P = 0.009). Importantly, after adjusting 
for these parameters and urinary hemoglobin, urine 
ALCAM was also a significant independent predictor 
of 3-year OS (Table 4; Model 2; P = 0.002). Of note, 
the multivariable prediction strength of urine ALCAM 
nearly matches that of tumor stage based on adjusted 
partial likelihood ratio Chi-square statistics (Figure 5A). 
By setting the age to 69 and the urine ALCAM to 2.06, 
we were able to calculate the interaction adjusted hazard 
ratios and confidence intervals for each of the parameters 
in the model; whereby, patients are at 1.5 times greater 
risk of death within 3 years following cystectomy if 
their urine ALCAM level is high (6.0 ng/ml) compared 
to low (0.75 ng/ml) (95% CI, 1.03–2.06; P = 0.002). 
Moreover, this effect is significantly modified by age 
(Table 4; Model 2, Urine ALCAM X Age, P = 0.031). 
To visualize this interaction, the adjusted effects of urine 
ALCAM were plotted at different age groups for patients 
with tumor stage 4, negative lymph-node status, and 
341 ng/ml of urine hemoglobin (Supplementary Figure 
S2A). Importantly, internal validation analyses revealed 
that there was no significant over-fitting of the models 
(Supplementary Figure S3A).
The ability of urine ALCAM to improve the prediction 
of 3-year OS (Model 2) when compared to standard 
predictors alone (Model 1) was assessed by graphing 
reclassification plots and time-dependent receiver operating 
characteristics curves (ROC) based on multivariable Cox 
regression analyses. Reclassification plots, where the 
predicted risk without urine ALCAM (Model 1) is plotted 
against the predicted risk with urine ALCAM (Model 2), 
showed that the addition of urine ALCAM was effective 
at reclassifying patients with high and low risk of death; 
whereby, event points (open circles) were mainly shifted 
above the diagonal and non-event points (black circles) were 
mainly shifted below the diagonal, which is in agreement 
with what is expected if there is improvement in risk 
prediction (Supplementary Figure S2B). Additionally, the 
computed continuous ½ net reclassification index (NRI) 
Group 120 0 120
 NMIBC 25.0% (30) 25.0% (30)
 OCMIBC 24.2% (29) 24.2% (29)
 EVMIBC 25.8% (31) 25.8% (31)
 LN+ 25.0% (30) 25.0% (30)
Death (Full 
Follow-up) 120 58 χ
2
1 = 9.53
c 0.002* 178
 0 40.8% (49) 65.5% (38) 48.9% (87)
 1 59.2% (71) 34.5% (20) 51.1% (91)
Death  
(3 years) 120 58 χ
2
1 = 2.37
c 0.147 178
 0 53.3% (64) 65.5% (38) 57.3% (102)
 1 46.7% (56) 34.5% (20) 42.7% (76)
Description and comparison of the retrospective bladder cancer patient cohorts used for prognostic assessment of shed 
ALCAM in serum and urine collected at VUMC and UTSW. a = Mann-Whitney U, b = Fisher’s Exact, c = Pearson Chi 
Square, * exact 2-tailed significance detected, Quartiles = 25%, Median, 75%, NMIBC = non-muscle invasive BCa, OCMIBC 
= organ-confined muscle invasive BCa, EVMIBC = extravesical muscle invasive BCa, LN+ = lymph-node positive muscle 
invasive BCa 
Oncotarget730www.impactjournals.com/oncotarget
[40] at 1 year post-surgery is 31.5% (95% CI, 0.00–0.52; 
P = 0.05), which indicates that 31.5% of patients see 
an improvement in risk prediction with the addition of 
urine ALCAM. Furthermore, the time dependent ROC 
curves show that over the 3 years of follow-up, there was 
a 3–5% increase in area under the curve (AUC) with the 
addition of urine ALCAM (Figure 5B). However, this is 
only true after the first 6 months of follow-up where it is 
speculated that, prior to this time, patient deaths are due 
to post-surgical complications and lack of recovery. There 
was also a 3.3% increase in Harrell’s Concordance Index 
(C-Index) [41] (Table 4; 75.2% vs. 78.5%). Additionally, 
after internal Bootstrap validation to correct for any over-
fitting, the inclusion of urine ALCAM still showed a 
clinically meaningful improvement of 2.5% in the C-Index 
(Table 4; 73.5% vs. 76.0%). Importantly, urine ALCAM still 
remained an independent predictor of OS after accounting 
for additional clinical features including treatment with 
BCG, presence of carcinoma in situ (CIS), extent of lymph-
node dissection, lymphovascular invasion, urine creatinine, 
and adjuvant chemotherapy (HR, 1.10; 95% CI, 1.02–1.19; 
P = 0.011; Table 4, Model 3).
In summary, the addition of urine ALCAM is 
an independent prognostic indicator and improves the 
prediction of post-cystectomy, 3-year overall survival of 
patients with BCa to a degree that is clinically relevant 
using the VUMC cohort.
Validation
In order to validate the VUMC cohort results, a 
similar retrospective BCa cohort containing matched 
Table 4: Assessment of urinary “shed” ALCAM as a predictor in a multivariable Cox regression 
analysis of 3-year overall survival in the VUMC bladder cancer cohort
Variable Hazard Ratio 95.0% CI Significance Bootstrap Significance
M
od
el
 1
Age (Years) 1.06a 1.03–1.10 < 0.001 0.001
Tumor Stage 1.28a 1.07–1.52 0.006 0.008
Lymph-node Positive 2.62a 1.27–5.38 0.009 0.016
Urine Hemoglobin (μg/ml) 1.00a 0.99–1.00 0.116 0.189
C-Index 75.2% 68.8–81.5 73.5Ψ
M
od
el
 2
Age (Years) 1.74b 1.05–2.87 < 0.001 0.001
Tumor Stage 1.98c 1.36–2.89 < 0.001 0.002
Lymph-node Positive 2.03 0.96–4.30 0.065 0.034
Urine Hemoglobin (μg/ml) 1.07d 0.93–1.23 0.329 0.729
Urine ALCAM (ng/ml) 1.46e 1.03–2.06 0.002 0.005
Urine ALCAM X Age* 0.031 0.023
C-Index 78.5% 72.4–84.6 76.0Ψ
M
od
el
 3
Age (Years) 1.06 1.02–1.11 0.004 0.020
Tumor Stage 1.37 1.06–1.76 0.015 0.022
Lymph-node Positive 1.60 0.64–4.02 0.314 0.343
Urine Hemoglobin (μg/ml) 1.00 0.99–1.00 0.435 0.529
Urine Creatinine (mg/dl) 1.00 0.99–1.00 0.875 0.889
Urine ALCAM (ng/ml) 1.10 1.02–1.19 0.011 0.018
BCG Treatment 0.62 0.29–1.36 0.233 0.310
CIS Present 1.79 0.86–3.72 0.119 0.129
# Lymph-nodes Removed 1.00 0.95–1.04 0.918 0.931
Lymphovascular Invasion 1.45 0.53–3.98 0.467 0.549
Adjuvant Chemotherapy 0.77 0.30–1.96 0.581 0.634
Assessment of urinary shed ALCAM as a predictor of 3-year overall survival by multivariable Cox regression analysis in 
the VUMC cohort. Hazard Ratio is the adjusted hazards ratio. CI, confidence interval. BCG, Bacillus Calmette-Guérin. CIS, 
carcinoma in situ. Bootstrap significance is two-tailed with 1000 iterations and a Mersenne twister of 2,000,000. Hazard 
ratio is the adjusted hazard ratio for a every 1 unit increase, b urine ALCAM at 2.06 ng/ml, but 13 years older, c 2 tumor stage 
increase, d 1.03 μg/ml higher urine hemoglobin, and e 69 year old with a 5.03 ng/ml increase in urine ALCAM. *, Interaction 
term. C-Index, Harrell’s Concordance Index [41]. Ψ, internal validation of the C-Index, confidence interval calculations not 
available.
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serum and urine collected at time of cystectomy was 
obtained from University of Texas Southwestern (Table 3; 
UTSW, n = 64). The UTSW and the VUMC cohorts were 
significantly different on several parameters including 
urine and serum ALCAM, urine hemoglobin, follow-up 
time, and race (Table 3). However, urine ALCAM was 
still significantly elevated in the UTSW cohort compared 
to normal controls (10.6-fold, p < 0.0001). The follow-
up for the UTSW cohort was shorter than the VUMC 
cohort (Table 3; median 12.5 vs. 38.1 months) but the 
3-year overall survival of the two cohorts were similar 
(Table 3). Since there were not enough events in the 
UTSW cohort for multivariable analysis (events = 20), 
we chose to combine the VUMC and UTSW cohorts to 
strengthen the generalizability of the prediction model 
(Table 3; events = 76).
Figure 3: Detection of shed ALCAM in biofluids of patients with bladder cancer. (A) The extracellular domain of ALCAM 
is cleaved from the cell surface by ADAM17 when tumor cells become invasive and can be detected in tumor-adjacent biofluids such as 
blood and urine. (B) ALCAM immunoblots of deglycosylated (PNGaseF) tumor cell lysates (WCL), conditioned media (CM) and urine 
(BCa 1 and BCa 2) probed with either antibodies to the extracellular domain (MOG/07) or intracellular domain (1G3A [23]) of ALCAM. 
Arrows indicate full-length (Intact ALCAM) and the cleaved ALCAM extracellular domain (ALCAM ECD). (C) ALCAM levels (ng/ml) 
in serum of normal controls compared to patients with BCa. (D) ALCAM levels (ng/ml) in urine of normal controls compared to patients 
with inflammatory conditions, cancers other than BCa, and BCa. Note segmented y-axis. UC, ulcerative colitis. SC, staghorn calculi. (E, 
F) Correlation of shed ALCAM in the serum (E) and urine (F) with pathological tumor stage in the VUMC shed ALCAM BCa cohort 
(n = 120). K-W, Kruskal-Wallis test. J-T, Jonckheere-Terpstra test for trend. Graphs display mean and 95% CI. 
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Again, in the combined cohort, age, tumor stage, 
and positive lymph-node status were all independent 
predictors of 3-year OS (Table 5; Model 1; P < 0.0001, 
 P = 0.003, P < 0.001). The interaction between urine 
ALCAM and age remained significant (Supplementary 
Figure S2C and Table 5; Model 2, Urine ALCAM X Age, P 
= 0.038). Importantly, urine ALCAM remained a significant 
independent predictor of 3-year OS after adjusting for 
baseline parameters and the age interaction (Table 5; 
Model 2; adjusted HR, 1.27; 95% CI, 1.05–1.52, P = 
0.001). Interaction adjusted hazard ratios and confidence 
intervals were calculated by setting the age to 69 and the 
urine ALCAM to 1.61 in the interaction term and revealed 
that patients have a 30% increased risk of death within 3 
years following surgery if their urine ALCAM levels are 
high (4.05 ng/ml) compared to low (0.69 ng/ml) (95% CI 
1.05–1.52, P = 0.001). Urine ALCAM still had similar 
prediction strength as tumor stage based on adjusted partial 
likelihood ratio Chi-square statistics (Figure 5C). Likewise, 
internal bootstrap validation revealed no significant over-
fitting of model 1 and model 2 for the combined cohort 
(Supplementary Figure S3B).
Furthermore, similar to the VUMC cohort alone, the 
addition of urine ALCAM in the multivariable model tended 
to increase the predicted risk for event patients and decrease 
the predicted risk for non-event patients, thus improving the 
classification (Supplementary Figure S2D). In addition, the 
combined cohort time-dependent ROC curves show that 
over the 3 years of follow-up, there was a 4–5% increase in 
AUC with the addition of urine ALCAM (Figure 5D). Most 
importantly, the addition of urine ALCAM in the multi-
institutional cohort still showed a clinically meaningful 
improvement of 2.4% in the C-Index and, after internal 
validation, this increase was still 1.6% (Figure 5D and Table 
5; C-Index, 76.1 vs. 78.5; bootstrap validation, 75.2 vs. 76.8).
As a final analysis, we performed multiple 
imputation using Bayesian Bootstrap Predictive Mean 
Matching (PMM) on the combined cohort as a method 
to estimate values for missing data. After multiple 
imputation, urine ALCAM remained an independent 
predictor of 3-year OS (Table 5; adjusted HR, 1.22; 95% 
CI, 1.00–1.49, P = 0.018).
In summary, we show that although the histological 
detection of ALCAM within the tumor tissue correlates 
Figure 4: Univariable correlation of shed ALCAM with tumor stage and overall survival in bladder cancer. Kaplan-
Meier curves and Log-rank tests for analysis of overall survival with tumor stage (A), urine ALCAM (B), and serum ALCAM (C). (A) High 
stage ≥ pT3 and low stage < pT3. (B, C) Serum and urine ALCAM were dichotomized as high and low around the median (serum = 74.9 
ng/ml and urine = 2.2 ng/ml). HR, Hazard Ratio. CI, Confidence Interval. (D) Univariable predictive power measured by Somers’ Dxy rank 
correlation with 3-year OS allowing censoring for each predictor.
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strongly with tumor stage in BCa (Figure 2), it does not 
appear to be prognostic of overall survival. In contrast, 
urine ALCAM correlates with tumor stage and is a 
significant independent predictor of 3-year overall survival 
for patients after cystectomy. All results are summarized 
in Figure 6, which emphasizes the discordance between 
correlation with stage and correlation with outcome.
DISCUSSION 
Although intervention can be curative for BCa 
patients, 50% of patients experience metastatic recurrence 
within two years following cystectomy [5]. Patient 
outcome could improve if: 1) patients with a low-grade, 
non-invasive BCa who are at risk of rapid progression 
could be identified for earlier radical surgical intervention 
and 2) patients with high-grade and/or invasive BCa 
at risk of metastatic recurrence could be identified for 
more aggressive intervention such as neo-adjuvant or 
adjuvant chemotherapy. Prognostic biomarkers can 
aid in identification of such high-risk patients. Urinary 
biomarkers have additional clinical value in that they 
provide a longitudinal and non-invasive means to monitor 
tumor progression, recurrence and treatment response. 
Molecular products that are mechanistically involved 
in or directly result from cell motility make particularly 
attractive biomarkers because tumor cell migration is a 
central driver of malignant progression and metastatic 
dissemination [42]. These molecular motility markers 
could predict or detect disease progression before 
overt clinical manifestation. ALCAM forms adhesive 
interactions between neighboring epithelial cells but 
cohesion is disrupted by membrane proximal, proteolytic 
cleavage and release of the ALCAM ectodomain from 
Table 5: Assessment of urinary “shed” ALCAM as a predictor in a multivariable Cox regression 
analysis of 3-year overall survival in the combined VUMC and UTSW bladder cancer cohort
Variable Hazard Ratio 95.0% CI Significance Bootstrap Significance
M
od
el
 1
Age (Years) 1.05a 1.03–1.08 < 0.0001 0.001
Tumor Stage 1.25a 1.08–1.45 0.003 0.001
Lymph-node Positive 2.95a 1.64–5.28 < 0.001 0.002
Urine Hemoglobin (μg/ml) 1.00a 0.99–1.00 0.073 0.072
C-Index 76.1% 70.7–81.4 75.2Ψ
M
od
el
 2
Age (Years) 1.58b 1.08–2.34 < 0.0001 0.001
Tumor Stage 1.75c 1.28–2.37 < 0.001 0.002
Lymph-node Positive 2.69 1.47–4.92 0.001 0.002
Urine Hemoglobin (μg/ml) 1.04d 0.97–1.12 0.278 0.463
Urine ALCAM (ng/ml) 1.27e 1.05–1.52 0.001 0.005
Urine ALCAM X Age* 0.038 0.014
C-Index 78.5% 73.4–83.7 76.8Ψ
M
ul
tip
le
 Im
pu
ta
tio
n Age (Years) 1.52
f 1.07–2.17 0.0002
Tumor Stage 2.34g 1.48–3.69 0.0003
Lymph-node (N Stage) 1.66h 1.24–2.21 0.0006
Urine Hemoglobin (μg/ml) 1.04i 0.95–1.13 0.408
Urine ALCAM (ng/ml) 1.22j 1.00–1.49 0.018
Urine ALCAM X Age* 0.078
Assessment of urinary shed ALCAM as a predictor of 3-year overall survival by multivariable Cox regression analysis in 
the combined VUMC and UTSW cohort. CI, confidence interval. Bootstrap significance is two-tailed with 1000 iterations 
and a Mersenne twister of 2,000,000. Hazard ratio is the adjusted hazard ratio for a every 1 unit increase, b urine ALCAM at 
1.61 ng/ml, but 8 years older, c 2 tumor stage increase, d 0.90 μg/ml higher urine hemoglobin, and e 69 year old with a 3.36 
ng/ml increase in urine ALCAM. *, Interaction term. C-Index, Harrell’s Concordance Index [41]. Ψ, internal validation 
of the C-Index, confidence interval calculations not available. Multivariable Cox regression analysis with Model 2 in the 
combined VUMC and UTSW cohort after replacement of missing data by multiple imputation via Bayesian Bootstrap 
Predictive Mean Matching (PMM) [51, 52]. Hazard ratio is the adjusted hazard ratio for f urine ALCAM at 1.72 ng/ml, but 
12 years older, g 3 tumor stage increase, h 1 lymph-node stage (N Stage, 0–3) increase, i 0.96 μg/ml higher urine hemoglobin, 
and j 69 year old with a 3.50 ng/ml increase in urine ALCAM.
Oncotarget734www.impactjournals.com/oncotarget
mobile tumor cells [20, 21]. Therefore, ALCAM shedding 
is not specific to bladder cancer. Rather, the shed 
extracellular domain of ALCAM is a marker of invasive 
and metastatic disease and, thus, has the potential to be a 
clinically relevant prognostic biomarker in many epithelial 
cancers.
In agreement with our results, two recent 
publications looking at the correlation of ALCAM tissue 
expression with stage and outcome in breast cancer 
also reveal a loss in detectable levels of ALCAM by 
immunohistochemistry as tumors progress [43, 44]. This 
is consistent with our hypothesis that the loss of detection 
is due to increases in ALCAM shedding as tumors 
become invasive. Indeed, another group has shown in 
a diagnostic study that patients with breast cancer have 
elevated serum levels of ALCAM [45]. However, it has 
yet to be demonstrated that ALCAM shedding correlates 
with stage or outcome in breast cancer. We previously 
demonstrated in colorectal cancer that reduced detection 
of the ALCAM extracellular domain in tumor tissue is 
due to ALCAM shedding which, in turn, corresponds with 
poor patient outcome [23].  Those observations suggested 
that detection of shed ALCAM in adjacent biofluids 
could predict disease progression. This hypothesis was 
tested in our evaluation of urinary ALCAM from BCa 
patients. Indeed, there is a significant loss of intra-tumoral 
ALCAM during invasive transformation (Figure 2), 
while urinary ALCAM levels rise and correlate with poor 
outcome (Figures 3 and 4) (Figure 6). Further statistical 
interrogation provides evidence that urinary ALCAM is a 
significant independent predictor of overall survival after 
adjusting for age, tumor stage, positive lymph-node status, 
and urinary hemoglobin (Table 4) and improves accuracy 
of prediction (i.e. discrimination) by 3.3% (Figure 5). 
Furthermore, this observation was validated in a combined 
multi-institutional cohort (Figure 5 and Table 5).
Although our main hypothesis is in regards to 
prognosis, it is interesting to note that in the current 
study, serum ALCAM has a diagnostic accuracy, an area 
under the receiver operating characteristics curve, of 0.75 
(p = 0.002, 95%CI 0.64–0.85) and urine ALCAM a 0.90 
(p < 0.0001, 95%CI 0.85–0.94) in distinguishing all-stage 
bladder from normal and inflammatory controls combined. 
As a comparison, cystoscopy and cytology together are 
80–99% accurate at diagnosing BCa and are more than 
commonplace in the clinic. Therefore, it is unlikely that 
shed ALCAM would provide any added diagnostic benefit 
in advanced, muscle-invasive bladder cancer. It would, 
Figure 5: Multivariable prediction of 3-year overall survival in bladder cancer. (A, C) Adjusted Chi-square statistics for all 
the variables in Model 2 for the VUMC cohort alone (A) and the combined VUMC and UTSW cohort (C). (B, D) Time-dependent receiver 
operating characteristic (ROC) curves for Model 1 (red) compared with Model 2 (blue) for the VUMC cohort alone (B) and the combined cohort 
(D). Concordance indices (C-Index). Vertical green dotted lines mark 12, 24 and 36 months. Black dotted line marks 0.80 (80%) concordance.
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however, be interesting to evaluate the diagnostic benefit 
of adding urine ALCAM to cytology in early-stage disease 
where cytology is much less accurate.
Our initial analysis was restricted to retrospective 
cohort studies based on the need for long-term follow-
up in prognostication. While the retrospective nature of 
this study poses limitations in regards to confidence in 
extrapolation to larger populations due to biases such as 
lack of racial and gender diversity, incomplete recurrence 
data, and confounding associated with reporting, sample 
collection, clinicians, and/or institutional practices, we 
have removed some potential biases by combining two 
independent cohorts collected at VUMC and UTSW. 
Furthermore, we have applied rigorous bootstrap 
validation methods and a team of biostatisticians 
has independently validated all statistical analyses. 
Interestingly, in a small subset analysis of the VUMC 
retrospective cohort (n = 40), urine ALCAM was an even 
stronger predictor of metastatic recurrence (HR = 10.4), 
which should be expected for a molecule that is indicative 
of invasive disease. Unfortunately, recurrence data and/or 
disease specific survival was not available for a majority 
of the patients. Larger multi-institution and multi-country 
prospective cohort studies are ongoing to validate the 
prognostic utility of urinary ALCAM in BCa and will 
require 3 years of enrollment and an additional 3–5 
years of follow-up. These prospective studies encompass 
repeated collection of biofluids and tissues over the course 
of progression, surgery, and (neo)adjuvant treatment, 
and will allow the tracking of cancer-specific outcome 
measures such as progression-free survival, treatment 
response, metastasis, and disease-specific survival. 
The correlation between ALCAM shedding and 
patient outcome suggests that this process contributes to 
disease progression. Thus, therapeutic targeting of this 
process could limit disease progression and improve 
patient outcome. The promiscuity and critical roles of 
the sheddase, ADAM17, limit the utility of targeting the 
protease directly. However, the proteolytic fragments 
released by the shedding event are hypothesized to convey 
their own biological activity. Studies investigating how 
these fragments alter the tumor phenotype and how that 
mechanism can be targeted for intervention are currently 
ongoing.
In summary, we provide evidence that shed ALCAM 
is an independent prognostic biomarker for overall 
survival in BCa. Our findings also suggest potential 
utility of shed ALCAM in longitudinal, post-diagnostic 
surveillance and monitoring of treatment response. 
Detection of shed ALCAM in tumor-adjacent fluids makes 
it a promising non-invasive and cost-effective biomarker 
in BCa as well as other cancers with tumor-associated 
biofluids. We further speculate that, although urine 
ALCAM is the predictor in non-metastatic BCa, ALCAM 
shed into the blood will have prognostic relevance in 
patients with metastatic disease. Furthermore, since 
ALCAM contributes mechanistically to cell migration 
and metastasis, our findings provide evidence that the 
molecular status of a migratory mechanism can report on 
the clinical risk of disease progression. Finally, findings 
Figure 6: Summary of the multi-level approach for analysis of ALCAM in bladder cancer. In the current study, we evaluate 
the prognostic significance of ALCAM mRNA, protein, and shedding in regard to overall survival in bladder cancer. The urothelium 
expresses an abundance of ALCAM. ALCAM is then cleaved from the cell surface by the protease ADAM17 during invasive progression 
of cancer. ALCAM shed from malignant urothelium should be detectable and elevated in adjacent fluids such as serum and urine. Our data 
supports the hypothesis that ALCAM shedding, which is a functional read-out of tumor cell migration and thus, invasion and metastasis, 
has greater prognostic value than its expression.
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from this study suggest that focusing on protein function 
rather than expression alone has the potential to aid in 
biomarker discovery, development and implementation.
MATERIALS AND METHODS
Specimen collection
All specimen collections were approved by the 
Vanderbilt (VUMC) and University of Texas Southwestern 
(UTSW) Institutional Review Boards (IRB) and patient 
confidentiality was protected according to the U.S. Health 
Insurance Portability and Accountability Act (HIPAA). 
All fluids were stored at -80˚C. Tissues were processed as 
standard diagnostic blocks and stored in the VUMC tissue 
library.
Study populations
ALCAM mRNA cohort
NCBI Gene Expression Omnibus (GEO, GSE31684) 
[32] was used to analyze ALCAM mRNA expression from 
excised cystectomy tumor tissue (probes 201951_at and 
201952_at) in BCa and included 93 patients, representing 
stages pTa to pT4, who underwent radical cystectomy 
at Memorial Sloan-Kettering Cancer Center between 
1993 and 2004. Median age of patients was 69.1 years, 
73% were male, median follow-up was 32 months, and 
incidence of death was 70%. In addition, 3 other BCa 
GEO datasets were utilized to compare ALCAM mRNA 
expression in non-muscle invasive to muscle invasive 
disease (GSE48276, GSE13507, GSE3167) [29–31].
ALCAM expression bladder cancer TMA cohort
Histological analysis of ALCAM protein expression 
was performed on a tissue microarray (TMA) from 
a retrospective cohort of patients undergoing radical 
cystectomy at VUMC from 2000–2010 for high-grade 
bladder cancer (301 patients, 657 total cores). The 
TMA was constructed from formalin-fixed, paraffin-
embedded cystectomy diagnostic tissue blocks. Each 
patient contributed between 1 and 6 cores to the array, 
with matched core designations of adjacent normal, 
superficial (pTa and pTis/Cis) and invasive (≥ pT1). 
Immunofluorescence staining for ALCAM was performed 
and correlation with overall survival was analyzed 
for those patients with a designated “invasive” core 
(n = 198). Correlation of ALCAM expression with core 
pathology stage was performed on all unique cores 
(n = 481) as described in statistical methods. The mean 
immunofluorescence calculation was used when a core 
designation was represented more than once for a single 
patient, such as multiple normal cores, which is why there 
were only 481 unique cores of the 651 total cores.
Shed ALCAM bladder cancer cohorts (VUMC)
The analysis of shed ALCAM in serum and urine, at 
time of surgery, was performed on a retrospective cohort of 
patients with high-grade bladder cancer undergoing radical 
cystectomy at VUMC from 2001–2006, which included 
pathological stages from pT0 to pT4 and excluded patients 
who had received neoadjuvant chemotherapy (n = 120).
Urine control cohorts
The following age-matched, control clean-catch or 
catheter-derived urine specimens were collected at VUMC 
by the Cooperative Human Tissue Network: 1) Non-
cancer control urines (Normal Controls) from patients 
with no history or current diagnosis of cancer undergoing 
non-urologic surgeries including cardiac bypass, gastric 
bypass, thyroidectomy, esophagomyotomy, knee 
replacement, and hernia repair, 2) Inflammation control 
urines (Inflammation) from patients with rectovaginal 
fistula, colorectal enteritis and ulceration, gallbladder 
polyploid cholesterolosis, endometriosis, atherosclerosis, 
ulcerative colitis, uterine fibroids, urethral stricture, and 
staghorn calculus, 3) Non-urologic cancer control urines 
(General Cancer) from patients with prostate, pancreatic, 
neuroendocrine, renal, and colorectal cancers.
Non-cancer serum control cohort
Serum from age-matched, non-cancer patients was 
collected from discarded vitamin D clinical tests in the 
Vanderbilt Clinical Chemistry laboratory.
Shed ALCAM bladder cancer cohort (UTSW)
For validation of urine ALCAM as a prognostic 
biomarker, our VUMC cohort was combined with a 
randomly selected retrospective cohort of patients with 
high-grade bladder cancer undergoing radical cystectomy 
at UTSW from 2005–2013, which included pathological 
stages from pT0 to pT4 (n = 64). Biofluids were collected 
at time of surgery.
Immunofluorescence
Immunofluorescence (IF) was performed on the 
tissue microarray described above. Sections (5µm) were 
deparaffinized and rehydrated. Antigen retrieval was 
performed by pressure cooker in citrate buffer (pH 6.0) 
and sections blocked in 20% Aquablock (East Coast 
Biologics) plus 0.05% Tween-20. IF was performed with 
primary antibodies mouse anti-ALCAM (MOG/07; 1:100; 
NovocastraTM, Leica Biosystems), rabbit anti-Ki67 (Clone 
SP6; 1:500; Thermo Scientific), and Hoechst 33342 as 
well as, secondary antibodies Alexa-546 goat anti-rabbit 
and Alexa-647 goat anti-mouse (1:500; LifeTechnologies). 
Collagen was stained with Alexa 488-conjugated 
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CNA35 (gift from Erin Rericha, Vanderbilt) [46, 47]. IF 
slides were mounted in ProLong Gold Antifade reagent 
(Invitrogen). Fluorescence intensity and thresholded area 
were quantified in the epithelium in each TMA core with 
an Image J-based batch macro. Collagen staining was used 
to distinguish between the epithelial, stromal and muscular 
compartments. Hoechst was used to define the nuclear 
compartment while Ki67 marked proliferating cells. 
Percent thresholded area of ALCAM was subsequently 
used for analysis.
Urine ALCAM normalization
In order to assess the influence of hydration, 
proteinuria, and hematuria on urinary ALCAM levels, 
we initially aimed to include all these parameters in the 
multivariable models. Urinary total protein (Thermo 
Scientific, BCA, Cat# 23227), urinary creatinine (Enzo 
Life Sciences, Cat# 937–001), urinary specific gravity 
(Siemens Medical Solutions Diagnostics, Multistix® 8 
SG, Cat# 2164) and urinary hemoglobin (Sigma-Aldrich, 
Drabkin’s Reagent, Cat# D5941) were all analyzed 
in a random subset of the VUMC cohort specimens. 
Unfortunately, the presence of urea made BCA analysis for 
total protein in urine unreliable and the limited dynamic 
range of specific gravity did not provide sufficient means 
to normalize. Urine creatinine neither added predictive 
value to the model nor altered the strength of urine 
ALCAM to predict overall survival. Therefore, only urine 
hemoglobin was considered in the final prediction model 
and analyzed in both the VUMC and UTSW cohorts.
ALCAM immunoblotting
Immunoblotting for shed ALCAM was performed 
on urine from two patients with bladder cancer, the whole 
cell lysates from the fibrosarcoma cell line HT1080 and 
the bladder cancer cell line UMUC-3 as well as, UMUC-
3 24-hour serum-free conditioned media. Urine and 
conditioned media were first precipitated with ice-cold 
acetone (1:4) at -20oC overnight, pelleted at 15,000 rpm 
for 15 minutes at 4oC, supernatant decanted and protein 
pellet air-dried for 15 minutes at room temperature. The 
protein pellet was then resuspended in lysis buffer (1.0% 
TritonX-100 in PBS) and sonicated at 37oC for 15 minutes. 
Next, all samples were deglycosylated using a PNGaseF 
kit according to the manufacturer’s instructions (P0704s; 
New England Biolabs). Deglycosylated samples were 
then run on two identical 12% polyacrylamide gels for 30 
minutes at 80 volts then 1.5 hours at 120 volts, transferred 
to a methanol-activated PVDF membrane in transfer 
buffer (25mM Tris, 192mM glycine, 20% methanol) for 
2 hours at 100 volts, and blocked overnight with 5% milk. 
One blot was probed with a mouse monoclonal antibody 
against the extracellular domain (MOG/07; 1:1000; 
Abcam) and the other with our previously characterized 
in-house mouse monoclonal antibody against the 
intracellular domain (1G3A; 1:2000) [23] overnight at 
4oC and then incubated with HRP-conjugated goat anti-
mouse antibody (1:2500; Abcam) for 1 hour at room 
temperature. Blots were developed with West Fempta 
Enhanced Chemiluminescence reagent for 5 minutes and 
photons read for a total of 15 minutes in a digital light box 
(G:BOX; Syngene).
ALCAM enzyme-linked immunosorbent assay
Serum and urine were analyzed by ALCAM ELISA 
according to the manufacturer’s protocol (R&D Systems). 
All samples were analyzed in duplicate at dilutions (Urine: 
4–8 fold; Serum: 50–80 fold) that matched the dynamic 
range of the assay (0.05–4.00 ng/ml).
Statistical analysis
Statistical analyses were performed at a two-tailed 
significance of 0.05. Descriptive statistics such as mean 
and 95% confidence interval (CI) for ALCAM mRNA 
expression among different cohorts were graphed. 
Kruskal-Wallis and/or Wilcoxon rank-sum (Mann-
Whitney U) tests were performed for comparing ALCAM 
mRNA level and ALCAM biofluid concentrations between 
independent groups such as different stages or cohorts. 
Jonckheere-Terpstra tests for non-independent groups 
were also used to assess trends of mRNA levels, protein 
levels or shed ALCAM concentrations with increasing 
tumor stage.  To evaluate the association of ALCAM 
protein expression with core stage in the BCa TMA 
cohort, generalized estimating equations (GEE) ordinal 
logistic regression was used in order to account for the 
representation of multiple core stages for each patient 
(non-independent samples). Kendall’s τ rank correlation 
was also calculated. Kaplan-Meier curves and log-rank 
tests were utilized for univariable survival analysis. 
To assess the value of urine ALCAM as a biomarker, 
multivariable Cox regression analyses were performed 
using the VUMC and UTSW cohort data to predict overall 
survival (OS) of bladder cancer patients after cystectomy. 
OS time was defined as time from the date of cystectomy 
to date of death or last follow-up and was restricted to 3 
years. The multivariable models were determined a priori 
based on each covariate’s potential to confound or modify 
the association between shed ALCAM and survival as 
well as data availability. Urine hemoglobin was included 
in the model to adjust for bleeding in the urine (hematuria) 
and account for any contamination of urine with serum 
ALCAM. In the models, tumor stage, age, hemoglobin 
and urine ALCAM were modeled as continuous variables 
and lymph-node status as a binary variable.  An interaction 
term between age and urine ALCAM was also included 
when the urine ALCAM was in the model. The models 
were internally validated using .632+ [48] bootstrapping 
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and calibration accuracy for 2- and 3-year survival was 
also estimated using bootstrapping. The model results were 
also compared with those fitted using multiple imputed 
data. Time-dependent receiver operating characteristics 
(ROC) curves [49], Harrell’s Concordance Index [41] 
and predicted risk scores were compared between models 
with and without urine ALCAM to assess the added value 
of urine ALCAM for discrimination in predicting patient 
survival. In addition, the continuous net reclassification 
index (NRI) was calculated using Uno’s package [40].
Statistical analyses and graphing were performed 
with SPSS (IBM), GraphPad Prism (GraphPad Software, 
Inc.) and R V 3.1.0 (http://www.R-project.org) [50] 
and several R packages, including “Hmisc”, “rms”, 
“survivalROC” and “survIDINRI”. Bootstrap validation 
was performed via SPSS with a two-tailed significance, 
1000 iterations and a Mersenne twister of 2,000,000 as 
well as in R as already described.
Impact
Beyond the initiating genetic event, cancer 
progression and metastasis is primarily controlled 
by alterations in the proteome. The cell migration 
machinery and its functional products not only contribute 
mechanistically to metastatic dissemination but also 
have the potential to serve as markers of invasive 
disease. While ALCAM has been postulated as such a 
biomarker, multiple studies have yielded contradicting 
results. The current study utilizes gene expression, 
immunofluorescence staining, and ELISA analysis of 
serum and urine to demonstrate that ALCAM shedding, 
but not expression, corresponds to patient outcome in 
bladder cancer. Furthermore, this multi-institutional 
cohort analysis reveals that shed urinary ALCAM is an 
independent prognostic indicator of overall survival in 
patients undergoing cystectomy. We are the first to suggest 
that urinary ALCAM can aid in the identification of high-
risk patients and in directing intervention. This data 
highlights the significance of focusing on protein function 
and post-translational events in identification of novel 
biomarkers.
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